Skip to main content

Table 2 Disease activity, clinical and laboratory features of the PULSE cohort

From: Pediatric systemic lupus erythematosus patients in South Africa have high prevalence and severity of cardiac and vascular manifestations

  Cardiac and vascular group (n = 45) Non-cardiac/vascular group (n = 48) P-value
Mean SLEDAI-2 K score (SD) 21.2 (7.2) 17.4 0.11
Lupus nephritis % (n) 66.7 (30) 58 (28) 0.407
Arthritis % (n) 58 (26) 64 (31) 0.501
Serositis % (n) 44 (20) 13 (6) <  0.001
Hypertension % (n) 38 (17) 27 (13) 0.270
ANA positive % (n) 100 (45) 92 (44) 0.117
Anti-dsDNA antibody positive % (n) 93 (42) 79.2 (38) 0.048
Anti-Sm antibody positive % (n) 35.6 (16) 25 (12) 0.267
Median C3 (g/l), range 0.9–1.80 0.90 1.00 0.89
Median C4 (g/l), range 0.1–0.4 0.11 0.10 0.94
  1. SLEDAI-2 K Systemic Lupus Erythematosus Disease Activity Index 2000, ANA Antinuclear Antibodies, dsDNA Double-stranded Deoxyribose Nucleic Acid, Sm Smith, C3 Complement 3, C4 Complement 4